Two anti-PDGFRα monoclonal antibodies, olaratumab (NCT00895180) and tovetumab,253 have been trialled in recurrent glioblastoma patients, but neither showed significant clinical activity (Table 1). Here, PDGFRA is linked to glioblastoma.